SMS Pharmaceuticals Limited
428.65
INR
-5.60
(-1.29%)
ISIN
INE812G01025
Return %
Stock
S&P 500
1Y
48.27
14.20
3Y
246.80
81.12
5Y
211.63
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Ramesh Babu Potluri
- Full Time Employees
- 2,088
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Trendset Jayabheri Connect Hyderabad TS India 500084
- IPO Date
- Feb 5, 2007
- Website
- smspharma.com
- Similar Companies
- Business
- SMS Pharmaceuticals Limited is an integrated pharmaceutical company specializing in the manufacture and export of Active Pharmaceutical Ingredients (APIs) and complex intermediates across multiple therapeutic categories including anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, and anti-retroviral segments. The company offers over 45 products to more than 800 customers in over 75 countries, with a global leadership position in 10+ therapeutic products. Key product offerings include APIs such as Ibuprofen, Tenofavir, Famotidine, Tadalafil, Levetiracetam, Lamotrigine, Sitagliptin, Rizatriptan Benzoate, Sumatriptan Succinate, and others, supported by USFDA, EUGMP, KFDA, CDSCO, and PMDA certifications. Founded in 1995 and headquartered in Hyderabad, India, SMS Pharmaceuticals operates several manufacturing facilities with a focus on quality through extensive quality management and regulatory compliance. In the last 1-2 years, SMS Pharmaceuticals has undertaken significant capacity expansion and vertical integration initiatives, including a ₹250 crore investment program aimed at scaling manufacturing, strengthening environmental systems, and enhancing new product introductions and contract manufacturing organization (CMO) business. The company continues to broaden its product portfolio, targeting the addition of 8-10 new products in existing and emerging therapeutic areas within the next 12-18 months. Recent strategic developments include successful inspections by regulatory authorities such as the USFDA, the expansion of a dedicated peptide-focused R&D center, and a greenfield CDMO site in Andhra Pradesh. It has also strengthened its market presence through a joint venture with Chemo and an investment in VKT Pharma to increase product offerings and deepen its footprint in Europe. SMS Pharmaceuticals focuses on leveraging a diversified product portfolio with a dual emphasis on high-margin and high-volume API products like Ibuprofen, where it aims for global scale leadership. The company prioritizes backward integration to improve profitability and cost efficiency while doubling its R&D expenditure over the coming period to support a robust pipeline of high-potential molecules, facilitated by multiple DMF, CEP, and dossier filings. The company maintains a strong export focus with extensive operations across international markets including the U.S., Europe, and Asia. This comprehensive operational and strategic approach positions SMS Pharmaceuticals as a leading API manufacturer with a solid foundation in regulatory compliance, global market reach, and ongoing capacity and product innovations, driven by sustained investment in research and infrastructure. Its continued focus on growth through capacity expansion, new product development, and strategic partnerships defines its current business trajectory.